Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 1953-1964

  Huizing, Manon T ^a   van Warmerdam, L J C ^a   Rosing, H ^a   Schaefers, M C W ^a   Lai, A ^a   Helmerhorst, T J M ^a   Veenhof, C H N ^a   Birkhofer, M J ^a   Rodenhuis, S ^a   Beijnen, J H ^a   ten Bokkel Huinink, W W ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIMETIDINE; CLEMASTINE; DEXAMETHASONE; DRUG METABOLITE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYALGIA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

EID: 0030986627     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.1953     Document Type: Article

References (32)

1. Neijt JP: New therapy for ovarian cancer. N Engl J Med 334:50-51, 1996
2. Vermorken JB, Hoekman K: Chemotherapy for gynecologic malignancies. Curr Opin Oncol 7:457-465, 1995
3. Vermorken JB, Ten Bokkel Huinink WW, Eisenhauer EA, et al: Carboplatin versus cisplatin. Ann Oncol 4:41-48, 1993 (suppl 4)
4. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequence of Taxol and cisplatin: A phase 1 and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
5. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
6. Ozols RF, Kilpatrick D, O'Dwyer P, et al: Phase I and pharmacokinetic study of Taxol and carboplatin in previously untreated patients with advanced epithelial ovarian cancer: A pilot study of the Gynecologic Oncology Group. Proc Am Soc Clin Oncol 12:259, 1993 (abstr)
7. Bookman MA, McQuire WP, Kilpatrick D, et al: Phase I Gynecologic Oncology Group (GOG) study of 3-h and 24-h paclitaxel with carboplatin as initial therapy for advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:271, 1995 (abstr)
8. Huizing MT, Van Warmerdam LJC, Rosing H, et al: Pharmacology of dose and sequence finding study of the combination paclitaxel and carboplatin in non-small cell lung cancer. Proc Am Soc Clin Oncol 14:367, 1995 (abstr)
9. Parker RJ, Dabholkar MD, Lee KB, et al: Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst 15:83-88, 1993
10. Rowinsky EK, Citardi MJ, Noe DA, et al: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents Taxol and vincristine. J Cancer Res Clin Oncol 119:727-733, 1993
11. Liebmann JE, Fisher J, Teague D, et al: Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6:25-31, 1994
12. Huizing MT, Keung ACF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
13. Willey TA, Bekos EJ, Gaver RC, et al: A high performance liquid Chromatographic procedure for the quantitative determination of paclitaxel in human plasma. J Chromatogr 621:231-236, 1993
14. Huizing MT, Sparreboom A, Rosing H, et al: Quantification of paclitaxel metabolites in human plasma. J Chromatogr 674:261-268, 1995
15. Van Warmerdam LJC, Van Tellingen O, Maes RAA, et al: Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 351:1820-1824, 1995
16. Proost JH, Meijer DKF: MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 22:155-163, 1992
17. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Dekker, 1982, pp 409-417
18. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
19. Sheiner LB, Beal SL: Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512, 1981
20. Gianni L, Kearns CM, Gianni A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J Clin Oncol 13:180-190, 1995
21. Van Warmerdam LJC, Rodenhuis S, Ten Bokkel Huinink WW, et al: The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol 121:478-486, 1995
22. National Institutes of Health Consensus Conference: Ovarian cancer: Screening, treatment and follow-up. JAMA 273:491-497, 1995
23. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
24. Pearl ML, Johnston CM, Reynolds RK, et al: Absence of cumulative bone marrow suppression in heavily pretreated ovarian cancer patients undergoing salvage chemotherapy with paclitaxel. Oncology 52:407-412, 1995
25. Shea T, Graham M, Bernard S, et al: A clinical and pharmacokinetic study of high dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. Semin Oncol 22:80-85, 1995 (suppl 5)
26. Calvert H, Boddy A, Bailey NP, et al: Carboplatin in combination with paclitaxel in advanced ovarian cancer: Dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 22:91-98, 1995 (suppl 5)
27. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 13:1860-1870, 1995
28. Kearns CM, Belani CP, Erkmen K, et al: Reduced platelet toxicity with combination carboplatin and paclitaxel; Pharmacodynamic modulation of carboplatin associated thrombocytopenia. Proc Am Soc Clin Oncol 14:170, 1995 (abstr)
29. Paul D, DeVore RD, Hande K, et al: Phase II trial of carboplatin and paclitaxel in advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:361, 1995 (abstr)
30. Creaven P, Raghavan D, Pendyala L, et al: Phase I study of paclitaxel and carboplatin: Implication for trials in head and neck cancer. Semin Oncol 22:13-16, 1995 (suppl 5)
31. Schiller JH, Storer B, Tutsch K, et al: Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony stimulating factor in patients with advanced cancer. J Clin Oncol 12:241-248, 1994
32. Chatelut E, Brunner V, Pujol A, et al: Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573-580, 1995